Clinical Pharmacology Details


Meningitis Vaccines


View Drug Forms

Indications & Dose:

Primary immunisation against Neisseria meningitidis 



Child 13–15 years: 0.5 mL for 1 dose, dose preferably injected into deltoid region


Immunisation against Neisseria meningitidis in an unimmunised patient



Child 10–17 years: 0.5 mL for 1 dose, booster dose is not required


Adult 18–24 years: 0.5 mL for 1 dose, booster dose is not required


Immunisation against Neisseria meningitidis in those at risk of exposure to prevent invasive disease



Child 3–11 months: 0.5 mL every month for 2 doses, dose preferably injected into deltoid region


Child 1–17 years: 0.5 mL for 1 dose, dose preferably injected into deltoid region Adult: 0.5 mL for 1 dose, dose preferably injected into deltoid region


Patients attending university for the first time (who have not received the routine meningococcal A, C,W135, and Y conjugate vaccine over the age of 10 years)



Adult 18–24 years: 0.5 mL for 1 dose continued’!


Primary immunisation against Neisseria meningitidis



Child 13–15 years: 0.5 mL for 1 dose, to be injected preferably into deltoid region


Immunisation against Neisseria meningitidis in an unimmunised patient 



Child 10–17 years: 0.5 mL for 1 dose, booster dose is not required


Adult 18–24 years: 0.5 mL for 1 dose, booster dose is not required


Immunisation against Neisseria meningitidis in those at risk of exposure 



Child 1–17 years: 0.5 mL for 1 dose, to be injected preferably into deltoid region (or anterolateral thigh in child 12–23 months), then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of Neisseria meningitidis serogroup A infection


Adult: 0.5 mL for 1 dose, to be injected preferably into deltoid region, then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of Neisseria meningitidis serogroup A infection


Patients attending university for the first time (who have not received the routine meningococcal A, C,W135, and Y conjugate vaccine over the age of 10 years) 



Adult 18–24 years: 0.5 mL for 1 dose

Contraindications:

Side Effects:

Rare Symptoms of meningitis reported (but no evidence that the vaccine causes meningococcal C meningitis)

Cautions:

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: